Peter Radovich joined Mirum in April 2020 as chief operating officer. In this role, he is responsible for commercial operations, technical operations, supply chain, and corporate development.
Prior to Mirum, he served as executive vice president, operations at Global Blood Therapeutics (GBT) from 2014 to 2020, encompassing the development, NDA submission and subsequent launch of Oxbryta ™ (voxelotor) tablets in sickle cell disease. During his tenure with GBT, he was responsible for the company’s technical operations, supply chain, program management and leadership, quality assurance, and commercial strategy and analytics functions. From 2006 to 2014, Peter worked at Onyx Pharmaceuticals, Inc. (now Amgen, Inc.) and served as vice president, global product leader, during which time he led the company’s global, cross-functional product team responsible for the development and commercialization of Kyprolis ®. In his time with Onyx, he also served in roles of increasing responsibility within the company’s commercial organization supporting Kyprolis and Nexavar ® and was a key member of the deal team for Onyx’s acquisition of Proteolix. Prior to Onyx, from 2004 to 2006, Peter served in product marketing roles at Chiron Corporation (now Novartis AG), supporting Proleukin ® (interleukin-2) in multiple oncology indications.
Peter received an MBA from Washington University in St. Louis and his undergraduate degree in biology and chemistry from Texas Christian University.